Patients Want Access to Care: Did Patients Have Challenges Engaging with the Tools?

In a heartwarming testimonial, Elva shares her experience using Carevive’s healthcare app during her cancer treatment. Downloading the app on her phone was simple, and she received regular texts from a supportive caregiver, making her feel fortunate to have a set day for check-ins. The app’s survey allowed her to share her symptoms, and she found comfort in receiving prompt responses with helpful recommendations to manage her discomfort. Even after answering the questions, the app provided valuable tips tailored to her needs. Elva appreciated the app’s ease of use, taking only a few minutes, whether she had a good or bad week. It allowed her to communicate her medication details and other symptoms, ensuring she felt heard and supported throughout her treatment journey.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…